Global demand for cancer surgery set to surge

January 24, 2021

Public health researchers, led by UNSW Sydney, have estimated the number of cancer cases requiring surgery globally each year, predicting the number will rise from 9.1 million to 13.8 million from 2018 to 2040 - an increase of 52 per cent or 4.7 million cases.

Their research shows the greatest relative increase will occur in 34 low-income countries, where the number of cases requiring surgery is expected to more than double by 2040 (314,355 cases to 650,164, or 107 per cent).

The modelling study, published in The Lancet Oncology on Friday, analysed global demand for cancer surgery and estimated surgical and anaesthesia workforce requirements between 2018 and 2040.

Lead author Dr Sathira Perera, a UNSW Scientia PhD scholar, said an absence of evidence-based estimates of future demand had restricted efforts to improve cancer care around the world.

Cancer is a leading cause of death and disability globally, and has substantial economic impacts, with recent evidence suggesting a disproportionate burden of disease in low- and middle-income countries.

"Our analysis has revealed that, in relative terms, low-income countries will bear the brunt of increased future demand for cancer surgery, bringing with it a need to substantially increase numbers of surgeons and anaesthetists," Dr Perera said.

"These findings highlight a need to act quickly to ensure that increasing workforce requirements in low-income countries are adequately planned for. There needs to be an increased focus on the application of cost-effective models of care, along with government endorsement of scientific evidence to mobilise resources for expanding services.

"In addition, access to post-operative care is strongly linked to lower mortality - so, improving care systems globally must be a priority in order to reduce the disproportionate number of deaths following complications."

The modelling study was an international collaboration between researchers from UNSW Sydney, University of Toronto, Kings College London, and the World Health Organization.

The researchers used best-practice guidelines, patient characteristics and cancer stage data to calculate the proportion of newly diagnosed cancer cases requiring surgery in 183 countries.

To predict future surgery demand, they applied these rates to GLOBACAN cancer incidence predictions from 2018 to 2040.

The study did not assess the impact of COVID-19, but the researchers acknowledge the delivery of high-quality post-operative care is more challenging during a pandemic.

Global shortage of surgeons, anaesthetists

To deliver cancer surgery services optimally now and in future, the researchers also predicted requirements for surgical and anaesthesia workforces.

To evaluate current staffing gaps, they compared the optimal estimated workforce (the median workforce of 44 high-income countries) with the number of surgeons and anaesthetists in each country.

Dr Perera said there was a current global shortage of 199,000 surgeons and 87,000 anaesthetists.

"This is based on the current workforce of 766,000 surgeons and 372,000 anaesthetists, compared with 965,000 and 459,000 needed for an optimal workforce, respectively, in our modelling study," he said.

"The gap is estimated to be greatest in low-income countries, where the current surgeon availability is 22,000 fewer than the model estimated optimal number of 28,000 surgeons.

"The current number of anaesthetists in low-income countries falls 11,000 below the model estimated demand of 13,000 anaesthetists."

Optimal workforce estimates for 2040

In recognition of the rising global demand for cancer surgery, the researchers also calculated estimates for the optimal surgical and anaesthesia workforces needed in 2040.

Extrapolating 2018 data, taking account of the predicted future cancer incidence burden in each country, their findings revealed the surgical workforce will need to increase from 965,000 in 2018 to 1.416 million in 2040 (a 47 per cent increase).

The anaesthetist workforce would need to rise from 459,000 in 2018 to 674,000 in 2040 (a 47 per cent increase).

The researchers found the greatest relative increase in optimal workforce requirements from 2018 to 2040 would occur in low-income countries, where surgeon numbers are required to rise from 28,210 to 58,219 by 2040 (106 per cent).

Anaesthetist numbers would also need to increase from 13,000 to 28,000 by 2040 (115 per cent).

Dr Perera said: "But to match the current benchmark of high-income countries, the actual number of surgeons in low-income countries would need to increase almost 400 per cent (from 6,000 to 28,000), and anaesthetists by almost 550 per cent (from 2000 to 13,000), of their baseline values.

"This is because the current workforce in low-income countries is already substantially smaller than in high-income countries."

Potential limitations

The researchers acknowledged that estimates in their study relied on several assumptions. Dr Perera said: "We based predictions of future cancer rates on 2018 estimates, but country-level changes - such as economic developments or altered capacity to screen for early diagnosis - could impact cancer incidence and therefore surgical demand and workforce requirements.

"Furthermore, observed gaps in the workforce could also be narrower than the actual gaps in practice - our predictions were conservative because we only considered initial surgical encounters without accounting for follow-up interactions."
-end-
Find the study in The Lancet Oncology: https://doi.org/10.1016/S1470-2045(20)30589-1

University of New South Wales

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.